Journal of Clinical Medicine (Jun 2020)

Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care

  • Joanne E. Mortimer,
  • Laura Kruper,
  • Mary Cianfrocca,
  • Sayeh Lavasani,
  • Sariah Liu,
  • Niki Tank-Patel,
  • Mina Sedrak,
  • Wade Smith,
  • Daphne Stewart,
  • James Waisman,
  • Christina Yeon,
  • Tina Wang,
  • Yuan Yuan

DOI
https://doi.org/10.3390/jcm9061984
Journal volume & issue
Vol. 9, no. 6
p. 1984

Abstract

Read online

The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer. Discoveries in the laboratory inform clinical trials which are the basis for improving the standard of care and are also the backbone for quality improvement. Clinical trials can be completed more rapidly by expanding trial enrollment to community sites. In this article we review some of the challenges in treating metastatic breast cancer with HER2-directed therapies and our strategies for incorporating our community partners into the research network.

Keywords